Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 4/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3943668 | 0.93 | TACR2 (0.38) | TACR2AOC3MEN1RAB9AKMT2A | |
| SCHEMBL3953427 | 0.90 | PLG (0.36) | PPARGPPARAKMT2APTGS2 | |
| SCHEMBL3951400 | 0.86 | TACR2 (0.41) | TACR2SIRT2SIRT1NAPEPLDALOX15 | |
| SCHEMBL3945792 | 0.85 | PLG (0.38) | TACR2AOC3MEN1RAB9AKMT2A | |
| SCHEMBL3949116 | 0.85 | PTGS2 (0.36) | PPARGPPARAPTGS2 | |
| SCHEMBL3946490 | 0.84 | PLG (0.37) | TACR2AOC3MEN1RAB9AKMT2A | |
| SCHEMBL3949403 | 0.84 | PLG (0.38) | PTGS2 | |
| SCHEMBL3949408 | 0.83 | PLG (0.36) | PPARGPPARAPTGS2 | |
| SCHEMBL1749618 | 0.83 | QPCT (0.36) | PPARGPPARARAB9ANAPEPLD | |
| SCHEMBL3949869 | 0.80 | MLYCD (0.34) | NAPEPLD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285568-B2 | Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-23 | — | — | US | claimed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | claimed |
| US-7582663-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2008-03-20 | — | — | US | disclosed |
| US-7285568-B2 | Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-23 | — | — | US | disclosed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | disclosed |
| EP-1567509-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048351-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | TACR2 1083/4885AOC3 2202/4885PPARG 1/4885 |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | TACR2 1124/4885AOC3 2177/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.